Cargando…
The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction
The high activity of Histone deacetylases (HDACs) in hepatocellular carcinoma (HCC) usually positively correlates with poor prognosis of patients. Accordingly histone deacetylases inhibitors (HDACis) are considered to be potential agents treating patients with HCC. In our study, we evaluated effect...
Autores principales: | He, Bin, Dai, Longfei, Zhang, Xiaoqian, Chen, Diyu, Wu, Jingbang, Feng, Xiaode, Zhang, Yanpeng, Xie, Haiyang, Zhou, Lin, Wu, Jian, Zheng, Shusen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231215/ https://www.ncbi.nlm.nih.gov/pubmed/30443188 http://dx.doi.org/10.7150/ijbs.27661 |
Ejemplares similares
-
JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
por: Heinicke, Ulrike, et al.
Publicado: (2015) -
miR-424-5p represses the metastasis and invasion of intrahepatic cholangiocarcinoma by targeting ARK5
por: Wu, Jingbang, et al.
Publicado: (2019) -
AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest
por: Zhou, Wei, et al.
Publicado: (2021) -
H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma
por: Yang, Beng, et al.
Publicado: (2018) -
Targeting Mybbp1a suppresses HCC progression via inhibiting IGF1/AKT pathway by CpG islands hypo-methylation dependent promotion of IGFBP5
por: Weng, Xiaoyu, et al.
Publicado: (2019)